Literature DB >> 26070289

Quality of life in patients with progressive supranuclear palsy: one-year follow-up.

Tatjana Pekmezović1, Milica Ječmenica-Lukić2, Igor Petrović2, Vladana Špica2, Aleksandra Tomić2, Vladimir S Kostić3.   

Abstract

The aim of this prospective cohort study that included 46 patients with progressive supranuclear palsy (PSP) was to estimate which demographic and clinical factors were the main contributors to the health-related quality of life (HRQoL) and how did the HRQoL change over a follow-up period of 1 year in these patients. The hierarchical regression analyses showed that the final models demonstrated that gender, included clinical variables and psychiatric/neuropsychological scales, accounted for 68% of the variance in the Physical Composite Score and 73% of the variance of the Mental Composite Score of the 36-item Short Form Health Survey (SF-36). Among variables in both final models, only the score of the Apathy Evaluation Scale showed statistically significant negative predictive value (p < 0.05). Changes in the HRQoL scores were assessed in 28 PSP patients who completed 1-year follow-up period after the baseline examination. Statistically significant decline in the HRQoL was detected for the following scales of the SF-36: physical functioning, vitality, social functioning, and role emotional, as well as in both composite scores (Physical Composite Score and Mental Composite Score). The analyses of magnitude of changes in the HRQoL during 1-year follow-up period showed large effect size (≥0.80) for total scores, as well as for the physical functioning, vitality, and social functioning. In conclusion, despite certain limitations, our study provided some new insights into potential predictors of the HRQoL and its longitudinal changes in patients with PSP.

Entities:  

Keywords:  Follow-up; Predictors; Progressive supranuclear palsy; Quality of life

Mesh:

Year:  2015        PMID: 26070289     DOI: 10.1007/s00415-015-7815-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment.

Authors:  M Köllensperger; M Stampfer-Kountchev; K Seppi; F Geser; C Frick; F Del Sorbo; A Albanese; T Gurevich; N Giladi; R Djaldetti; A Schrag; P A Low; C J Mathias; W Poewe; G K Wenning
Journal:  Eur J Neurol       Date:  2007-01       Impact factor: 6.089

2.  Assessment of quality of life with the multiple system atrophy health-related quality of life scale.

Authors:  Wassilios G Meissner; Alexandra Foubert-Samier; Sandrine Dupouy; Angélique Gerdelat-Mas; Rachel Debs; Fabienne Marquant; Valérie Cochen De Cock; Olivier Rascol; François Tison; Anne Pavy-Le Traon
Journal:  Mov Disord       Date:  2012-10-02       Impact factor: 10.338

3.  Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy.

Authors:  N J Cordato; C Pantelis; G M Halliday; D Velakoulis; S J Wood; G W Stuart; J Currie; M Soo; G Olivieri; G A Broe; J G L Morris
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

4.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

5.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy.

Authors:  Barbara Borroni; Antonella Alberici; Chiara Agosti; Maura Cosseddu; Alessandro Padovani
Journal:  Int Psychogeriatr       Date:  2009-03-27       Impact factor: 3.878

10.  Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy.

Authors:  Federica Agosta; Sebastiano Galantucci; Marina Svetel; Milica Ječmenica Lukić; Massimiliano Copetti; Kristina Davidovic; Aleksandra Tomić; Edoardo G Spinelli; Vladimir S Kostić; Massimo Filippi
Journal:  J Neurol       Date:  2014-03-06       Impact factor: 4.849

View more
  10 in total

1.  Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.

Authors:  Alexander Pantelyat; Lenora Higginbotham; Liana Rosenthal; Diane Lanham; Vanessa Nesspor; Mina AlSalihi; Jee Bang; Jiangxia Wang; Marilyn Albert
Journal:  Neurodegener Dis       Date:  2021-03-31       Impact factor: 2.977

2.  Mental Component Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males.

Authors:  X Ding; E L Abner; F A Schmitt; J Crowley; P Goodman; R J Kryscio
Journal:  J Prev Alzheimers Dis       Date:  2021

3.  Characteristics of Nonmotor Symptoms in Progressive Supranuclear Palsy.

Authors:  Ruwei Ou; Wei Song; Qianqian Wei; Ke Chen; Bei Cao; Yanbing Hou; Bi Zhao; Huifang Shang
Journal:  Parkinsons Dis       Date:  2016-06-05

Review 4.  Managing cognition in progressive supranuclear palsy.

Authors:  Timothy Rittman; Ian Ts Coyle-Gilchrist; James B Rowe
Journal:  Neurodegener Dis Manag       Date:  2016-11-23

5.  Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants.

Authors:  Duncan Street; Maura Malpetti; Timothy Rittman; Boyd C P Ghosh; Alexander G Murley; Ian Coyle-Gilchrist; Luca Passamonti; James B Rowe
Journal:  Brain Commun       Date:  2021-09-02

6.  Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy.

Authors:  Sophia Rogozinski; Martin Klietz; Gesine Respondek; Wolfgang H Oertel; Michel J Grothe; Joana B Pereira; Günter U Höglinger
Journal:  Front Aging Neurosci       Date:  2022-04-01       Impact factor: 5.702

7.  Double Product and Autonomic Function as Predictors of Quality of Life in Heart Transplant Recipients: A Cross-Sectional Study.

Authors:  Luiz Fernando Rodrigues; Beatriz Robert Moreira; Alice Pereira Duque; Juliana Rega de Oliveira; Pedro Henrique Scheidt Figueiredo; Cláudia Rosa de Oliveira; Alexandre Siciliano Colafranceschi; Mauro Felippe Felix Mediano; Tereza Cristina Felippe Guimarães
Journal:  Braz J Cardiovasc Surg       Date:  2022-08-16

8.  Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes.

Authors:  Alexander G Murley; Matthew A Rouse; Ian T S Coyle-Gilchrist; P Simon Jones; Win Li; Julie Wiggins; Claire Lansdall; Patricia Vázquez Rodríguez; Alicia Wilcox; Karalyn Patterson; James B Rowe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-02-09       Impact factor: 13.654

Review 9.  SF-36 total score as a single measure of health-related quality of life: Scoping review.

Authors:  Liliane Lins; Fernando Martins Carvalho
Journal:  SAGE Open Med       Date:  2016-10-04

10.  Brain gray matter abnormalities in progressive supranuclear palsy revisited.

Authors:  PingLei Pan; Yi Liu; Yang Zhang; Hui Zhao; Xing Ye; Yun Xu
Journal:  Oncotarget       Date:  2017-09-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.